You just made all that up. Here is what Prana said on the subject.
"Prana is determining the optimal commercialisation pathway of PBT2 including securing a collaboration to undertake the further non-clinical work needed to pave the way to start a Phase 3 Huntington disease trial, the use of PBT2 at lower doses (as currently permitted by the FDA), or using PBT2 for acute indications requiring shorter term use, all with the aim of realising shareholder value from this part of its IP portfolio."
Progress, page-35
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $12.53K | 4.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13926044 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 153031722 | 56 |
View Market Depth
| Last trade - 14.56pm 19/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |